Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.
Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.
Read publication: BJD
Related
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacoki...
0 Comments